Unicorn Asset Management Regulatory News (UAV)

Unicorn AIM VCT plc ("The Company")

Half-Yearly Report Announcement for the six months ended 31 March 2023

Financial Highlights

For the six months ended 31 March 2023

· Net Asset Value ("NAV") total return per share for the six months ended 31 March 2023, after adding the back the dividends paid in the period, was -4.3%.

· £2.1 million of qualifying investments (£2.0 million new, £0.1 million follow-on) made in the period.

· Interim dividend of 3.0p per share declared for the six months ended 31 March 2023.

· The Offer for Subscription, launched on 24 January 2023, was oversubscribed by 6 February 2023, and raised £14.6 million (after costs of £0.4 million).

Fund Performance

* Shareholders' funds/net assets as shown in the Condensed Statement of Financial Position below.

** Total dividends (including special dividends) paid since 30 September 2013.

Chair's Statement

I am pleased to present the unaudited Half-Yearly Report of the Company for the six-month period ended 31 March 2023.

As at 31 March 2023, the net assets of the Company were £218.4 million. This figure is £2.7 million lower than at the start of the current financial year. After accounting for the additional shares in issue following a successful Offer for Subscription and after adding back dividends paid in the period, the total return in the six-month period under review was -4.3%.

The decline in net asset value recorded in the first half of the Company's financial year is both disappointing and represents a period of relative underperformance. The FTSE AIM All-Share Index recorded a small positive total return of 1.1%.

Investor appetite for equity risk continued to wane throughout the first half of the financial year and this resulted in a significant derating of smaller, less liquid AIM stocks and a widening divergence of returns across the market capitalisation range. On average during the period, there were twenty-two companies listed on the AIM Index with a market capitalisation in excess of £1 billion. The value of these companies, represented 26% of the total value of the AIM Index and they posted an average total return of +20.4% over the six-month period under review. By contrast, there were 653 companies valued at a market capitalisation of £150m or less, in aggregate accounting for only 23% of AIM Index value.

These smaller businesses posted an average total return of -9.8% over the same period. Such statistics illustrate the divergence in performance between smaller, earlier stage growth companies, where the majority of our investments must be directed, and the larger, more established businesses listed on the AIM Index.

Higher interest rates have weighed particularly heavily on early-stage growth companies, where valuations are typically more dependent on longer term expectations of profitability. This dynamic has placed significant pressure on the share prices of many AIM-listed companies. Larger, more established businesses, especially those listed on the FTSE 100 Index, again significantly outperformed companies at the lower end of the market capitalisation range.

Inevitably, there were also a small number of discouraging trading updates in the six months under review. Nonetheless, the period can best be characterised by the resilience and adaptability shown by most investee companies despite the extremely challenging operating conditions environment. The most notable exception was The British Honey Company ("British Honey"), a UK based producer of spirits, honey, and jams. A weak balance sheet, combined with poor operational management, exacerbated the mounting challenges posed by order delays, a difficult consumer environment and severe cost inflation. At the end of March, the Board of British Honey announced its intention to place the business into administration in order to avoid trading insolvently. Although British Honey has been an extremely disappointing investment, the impact on performance in the period was minimal due to declines in British Honey's carrying value in previous periods. It is now highly unlikely that any meaningful recovery in value will be achieved.

Your Investment Manager continues to manage the portfolio in a prudent fashion with the aim of developing a diverse portfolio of high-quality companies capable of generating significant Shareholder returns over the long term. The team at Unicorn has extensive experience of investing in AIM listed businesses across the full spectrum of market conditions and they are well placed to successfully navigate the current challenging environment.

Investment Performance

A review of the ten most meaningful contributions to performance in absolute terms (both positive and negative) follows.

Hasgrove (11.1% of net assets, +£5.4 million) is an unquoted company, whose sole operating subsidiary, Interact, is a fast-growing Software as a Service (SaaS) provider of corporate intranet solutions. Hasgrove reported strong results for its financial year ended 31 December 2022, during which revenues grew by 28% to £29.4 million and adjusted EBITDA increased by 22% to £10.1 million. Management also reported a strong start to trading in the current financial year, underpinned by high levels of recurring revenue from its core Interact software product. As a result, further growth is anticipated in the current financial year ended 31 December 2023, and the Fair Value of the Company's holding in Hasgrove has therefore been adjusted upwards to £24.3 million. This uplift represents an increase of £5.4 million compared to the assessed Fair Value as at the VCT's previous financial year ended 30 September 2022.

Aurrigo International (3.7% of net assets, +£4.8 million) is a leading international provider of transport technology solutions and is highly regarded as a specialist in autonomous and semiautonomous solutions. Aurrigo International has delivered strong operational and financial performance following its IPO on AIM in September 2022. Since its IPO, Aurrigo has invested in the further development of its Autonomous and Aviation division and signed an agreement with Singapore's Changi Airport Group for the next development phase of its 'Auto-Dolly' baggage transportation solution.

MaxCyte (4.3% of net assets, -£4.5 million) is a US-based life sciences company that provides cell engineering and gene editing technologies to support drug discovery and cell therapy applications. During the period, MaxCyte released results for its financial year ended 31 December 2022, which highlighted a 31% growth in revenues to $44.3 million. The aggregate potential value of all milestone payments is now reported to have increased to over $1.55 billion from eighteen strategic platform licence (SPL) agreements. The management team expects further revenue growth of between 21% to 26% in its current financial year. MaxCyte remains well-funded with total cash and cash equivalents of circa $227 million as at 31 December 2022. However, sentiment towards biotech companies has deteriorated markedly in the past two years and MaxCyte has certainly not been immune from this process, despite encouraging operational and financial performance.

Anpario (1.7% of net assets, -£4.0 million) is an international manufacturer and distributor of natural animal feed additives for animal health and nutrition, with a focus on sustainable and eco-friendly solutions. Anpario reported a weaker operational and financial performance in recent months, announcing a 25% decline in its gross profits due to supply chain disruption and significant inflation in the cost of raw materials. Sales growth across Asia, Middle East & Africa, and the Americas has been offset by a decrease in European revenues. Despite this recent setback, the business, remains profitable, maintains a strong balance sheet, offers a broad range of products and is geographically diverse. Your Investment Manager believes that the share price is likely to recover strongly once the current headwinds abate.

Abcam (5.8% of net assets, -£3.0 million) is a UK-based life sciences company that produces and distributes research-grade antibodies and other biological reagents for use in scientific research and diagnostics. In December 2022, Abcam delisted from the AIM Index, and we consequently exchanged our UK listed shares for an equivalent value of American Depository Shares. Abcam had been dual listed on AIM and NASDAQ since October 2020. In March 2023, Abcam released results for its financial year ended 31 December 2022, which highlighted that profit growth had been constrained by two main factors; the implementation of a new ERP system, which disrupted sales in September and October, and sales performance in China that was disrupted by the regime's zero-COVID policy.

Saietta (0.5% of net assets, -£1.9 million) is a designer and manufacturer of axial flux motors for electric vehicles. Unfortunately, Saietta was forced to issue a profit warning in March 2023, due to significantly weaker than expected sales in its Comet (heavy-duty) and Propel (Marine) divisions. Meanwhile, orders for Saietta's light-duty integrated eDrive product have been expanding at pace, requiring significantly increased investment to ensure a successful transition to volume manufacturing. The Board of Saietta has confirmed its confidence that the business is in a position to fully finance the current financial year (2023/24), without recourse to further external fundraising. Saietta's cash balance as at 28 February 2023 was £11 million.

Surface Transforms (2.4% of net assets, -£1.8 million) designs and manufactures high-performance carbon ceramic brake discs for use in the automotive and aerospace industries. In January 2023, Surface Transforms reported on technical problems, which included an issue with one of its key furnaces. These problems have adversely affected output over the past six months, which was already under pressure due to industry-wide supply chain constraints. These issues negatively affected turnover, have increased production costs, and have consequently resulted in a larger than expected operating loss for the company's financial year ended 31 December 2022. The management team has taken various steps to improve the manufacturing process, including the use of more readily available raw materials. These changes have been successfully implemented, and production issues therefore now appear to have been resolved.

Engage XR (0.3% of net assets, -£1.6 million) is a technology business focused on Virtual Reality. In December 2022, Engage XR issued a weaker than expected trading update, which reported on slow conversion of the group's sales pipeline. Engage XR had previously increased its cost base by expanding its sales, marketing, and support teams, which led to sharply higher losses in its financial year ended 31 December 2022. Management is now taking action to reduce the cost base in light of the more challenging trading environment.

Animalcare (1.2% of net assets, -£1.5 million) is an international animal health business. In March 2023, Animalcare announced results for its financial year ended 31 December 2022, which highlighted a modest decline in annual sales, primarily as a result of reduced antibiotic use in Spain. Animalcare has, however, made good progress in increasing its gross margins through sales of higher margin products and its Board expects to report on a return to revenue growth in the current financial year.

Angle (0.3% of net assets, -£1.3 million) is a world-leading liquid biopsy company. Angle has not been immune from the wider economic and market headwinds and the management team has therefore taken swift action to control the cost base, which has included the closure of its Canadian operations. These measures are expected to deliver cost savings of £2.6 million in 2023 and £4.0 million per annum thereafter but have also resulted in one-off costs of circa £2 million. Angle ended 2022 with net cash of circa £32 million.

In aggregate, the eight largest detractors from performance delivered an unrealised capital loss of £19.6 million, while the two largest contributors to performance contributed £10.2 million to positive performance.

Investment Activity

Investment activity is deliberately tightly controlled when the outlook for equity markets looks unsettled. Consequently, there has been limited investment activity during the period under review.

One new VCT qualifying investment into Oxford Biodynamics was completed in the six-month period to the end of March,2023 at an investment cost of £2.0 million. In addition to this new investment, one secondary investment was made in SulNOx at a cost of £0.1 million.

The Investment Manager continues to engage with the management teams of our investee companies on a regular basis, in order to monitor their performance and ensure that they are navigating the currently tough economic conditions as effectively as possible.

It is also important to note that new opportunities to create long term value are not being overlooked and, although the IPO market is currently subdued, the near-term investment pipeline remains encouraging.

Offer for Subscription

The Company's latest Offer for Subscription was launched on 24 January 2023 and opened for applications on 6 February 2023. The Offer reached full subscription of £15 million on 6 February 2023 and was closed shortly thereafter. On behalf of the Board, I would like to welcome all new Shareholders and to thank existing Shareholders for their continued support.

Dividends

The Board has declared an interim dividend of 3.0 pence per share, for the six months ended 31 March 2023. This interim dividend will be paid on 11 August 2023 to Shareholders on the register on 14 July 2023. The shares will be quoted ex-dividend on 13 July 2023.

Dividend decisions are taken by the VCT Board and are always subject to a number of factors including; market conditions, satisfactory returns, and/or availability of cash and distributable reserves.

Dividend Reinvestment Scheme ("DRIS")

On 14 February 2023, 560,504 Ordinary Shares were allotted at a price of 129.7 pence per share, being the latest published net asset value at 31 January 2023, to Shareholders who elected to receive Ordinary Shares under the DRIS as an alternative to the final cash dividend for the year ended 30 September 2022.

Share Buybacks

During the period from 1 October 2022 to 31 March 2023, the Company bought back 1,587,397 of its own Ordinary Shares for cancellation, at an average price of 114.8 pence per share including costs.

As at 31 March 2023, there were 174,104,558 Ordinary Shares in issue.

Material Transactions

Other than the Offer for Subscription, Share Buybacks and the purchase of investments described above, there were no material transactions in the six-month period ended 31 March 2023.

VCT Status

The Company comfortably exceeded the VCT qualifying threshold required by HM Revenue & Customs, with approximately 99.4% (excluding new capital) of total assets by VCT value being invested in VCT qualifying companies at the end of the period under review. The Company has complied with all other HM Revenue & Customs' regulations, and your Board has been advised by PwC that the Company has maintained its venture capital trust status.

Summary & Outlook

Small AIM-listed businesses continue to experience significant pressures. Access to growth capital is difficult, debt funding costs are high and input costs, such as wages and raw materials, have spiralled upwards. Against this backdrop, it is unsurprising that investor enthusiasm for early-stage, loss-making companies remains fragile.

However, there are reasons to believe that the outlook is improving. Inflation appears to have peaked, which should negate the need for significant interest rate increases. Pressures on the global supply chain have eased, which is enabling businesses to fulfil vital orders. Despite the gloomy forecasts from most economists, the UK economy has so far managed to avoid falling into recession and, for the time being at least, stability also appears to have been restored in Westminster. UK quoted companies generally remain in good financial health and continue to demonstrate their operational and financial resilience.

The FTSE AIM All-Share Index has suffered a significant contraction in value over the past two years which, although understandable, has been disproportionate to other equity markets. Encouragingly, in the early weeks of the second half of the VCT's financial year, equity market conditions have shown tentative signs of recovery, perhaps in response to an increased level of interest from prospective acquirers of UK listed businesses. Merger & Acquisition and IPO activity has certainly picked up noticeably in recent weeks.

The Board believes that the Company's investment portfolio is well placed to deliver a strong recovery in performance as and when these positive trends gather momentum.

Tim Woodcock

Chair

30 May 2023

Investment Objective

The Company's objective is to provide Shareholders with an attractive return from a diversified portfolio of investments, predominantly in the shares of AIM quoted companies, by maintaining a steady flow of dividend distributions to Shareholders from the income as well as capital gains generated by the portfolio.

It is also the objective that the Company should continue to qualify as a Venture Capital Trust, so that Shareholders benefit from the taxation advantages that this brings. To achieve this at least 80% for accounting periods commencing after 6 April 2019 (previously 70%) of the Company's total assets are to be invested in qualifying investments of which 70% by VCT value (30% in respect of investments made before 6 April 2018 from funds raised before 6 April 2011) must be in ordinary shares which carry no preferential rights (save as permitted under VCT rules) to dividends or return of capital and no rights to redemption.

In order to achieve the Company's investment objective, the Board has agreed an investment policy which requires the Investment Manager to identify and invest in a diversified portfolio, predominantly of VCT qualifying companies quoted on AIM that display a majority of the following characteristics:

experienced and well-motivated management;

products and services supplying growing markets;

sound operational and financial controls; and

potential for good cash generation in due course, to finance ongoing development and support for a progressive dividend policy.

Asset allocation and risk diversification policies, including maximum exposures, are to an extent governed by prevailing VCT legislation. No single holding may represent more than 15% (by VCT value) of the Company's total investments and cash, at the date of investment.

There are a number of VCT conditions which need to be met by the Company which may change from time to time. The Investment Manager will seek to make qualifying investments in accordance with such requirements.

Where capital is available for investment while awaiting suitable VCT qualifying opportunities or is in excess of the 80% VCT qualification threshold for accounting periods commencing after 6 April 2019, it may be held in cash or invested in money market funds, collective investment vehicles or non-qualifying shares and securities of fully listed companies registered in the UK.

To date the Company has operated without recourse to borrowing. The Board may however consider the possibility of introducing modest levels of gearing up to a maximum of 10% of the adjusted capital and reserves, should circumstances suggest that such action is in the interests of Shareholders.

Venture Capital Trust Status

The Company has satisfied the requirements for approval as a Venture Capital Trust ("VCT") under section 274 of the Income Tax Act 2007 (ITA). It is the Directors' intention to continue to conduct the business of the Company so as to maintain compliance with that section.

* Based on fair value not VCT carrying value

The important events that have occurred during the period under review and the key factors influencing the financial statements are set out in the Chair's Statement above.

In accordance with DTR 4.2.7, the Directors consider that with the exception of those mentioned below, the principal risks and uncertainties facing the Company have not materially changed since the publication of the Annual Report and Accounts for the year ended 30 September 2022.

The principal risks faced by the Company include, but are not limited to:

• investment and strategic

• regulatory and tax

• operational

• fraud, dishonesty and cyber

• financial instruments

• economic and political

In addition, the Directors also assess the possibility of new and emerging risks.

A more detailed explanation of these risks and the way in which they are managed can be found in the Strategic Report on pages 31 and 32 and in the Notes to the Financial Statements on pages 79 to 81 of the 2022 Annual Report and Accounts - copies can be found via the Company's website, www.unicornaimvct.co.uk.

Directors' Statement of Responsibilities in Respect of the Financial Statements

In accordance with Disclosure and Transparency Rule (DTR) 4.2.10, Tim Woodcock (Chair), Charlotta Ginman (Senior Independent Director), Jeremy Hamer (Chair of the Audit Committee) and Josie Tubbs, the Directors, confirm that to the best of their knowledge:

● the condensed set of financial statements, which have been prepared in accordance with FRS 104 "Interim Financial Reporting" give a true and fair view of the assets, liabilities, financial position and loss of the Company for the period ended 31 March 2023, as required by DTR 4.2.4;

● this Half-Yearly Report includes a fair review of the information required as follows:

the interim management report included within the Chair's Statement and the Investment Portfolio Summary, includes a fair review of the information required by DTR 4.2.7 being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties facing the Company for the remaining six months of the year; and

there were no other related party transactions in the first six months of the current financial year that are required to be disclosed in accordance with DTR 4.2.8.

This report may contain forward looking statements with regards to the financial condition and results of the Company, which are made in the light of current economic and business circumstances. Nothing in this report should be construed as a profit forecast.

The Half-Yearly Report was approved by the Board of Directors on 30 May 2023 and the above responsibility statement was signed on its behalf by:

Tim Woodcock

Chair

30 May 2023

The Board has overall responsibility for the Company's affairs including the determination of its investment policy. Risk is spread by investing in a number of different businesses across different industry sectors. The Investment Manager, Unicorn Asset Management Limited, is responsible for managing sector and stock specific risk and the Board does not impose formal limits in respect of such exposures. However, in order to maintain compliance with HMRC rules and to ensure that an appropriate spread of investment risk is achieved, the Board receives and reviews comprehensive reports from the Investment Manager on a monthly basis. When the Investment Manager proposes to make any investment in an unquoted company, the prior approval of the Board is required. The Board continues to take the need for transparency and independence seriously. When a conflict arises involving a relationship between any Director and an investee or proposed investee company, that Director abstains from any discussion or consideration on any such investment by the Company.

The Administrator, ISCA Administration Services Limited, provides Company Secretarial and Accountancy services to the Company.

All revenue and capital items in the above statement derive from continuing operations of the Company.

The total column of this statement is the Statement of Total Comprehensive Income of the Company prepared in accordance with Financial Reporting Standards ("FRS"). The supplementary revenue return and capital return columns are prepared in accordance with the Statement of Recommended Practice ("AIC SORP") issued in July 2022 by the Association of Investment Companies.

Other than revaluation movements arising on investments held at fair value through Profit or Loss Account, there were no differences between the (loss)/profit as stated above and at historical cost.

The notes form part of these Half-Yearly financial statements.

The financial information for the six months ended 31 March 2023 and the six months ended 31 March 2022 have not been audited.

The notes form part of these Half-Yearly financial statements.

The financial information for the six months ended 31 March 2023 and the six months ended 31 March 2022 have not been audited.

The profit and loss account comprises the revenue reserve of £(825,000) and the realised capital reserve of £11,610,000.

\* The special reserve and profit and loss account are distributable to Shareholders. The special reserve is used to fund market purchases of the Company's own shares, to make distributions and to write-off existing and future losses.

The notes form part of these Half-Yearly financial statements.

The financial information for the six months ended 31 March 2023 and the six months ended 31 March 2022 have not been audited.

The notes form part of these Half-Yearly financial statements.

1. Principal accounting policies

In order to better reflect the activities of a VCT and in accordance with the SORP, supplementary information which analyses the Income Statement between items of a revenue and capital nature has been presented alongside the Statement of Comprehensive Income. The revenue column of loss attributable to Shareholders is the measure the Directors believe appropriate in assessing the Company's compliance with certain requirements set out in Section 274 Income Tax Act 2007.

All investments held by the Company are classified as "fair value through profit or loss", in accordance with FRS102. This classification is followed as the Company's business is to invest in financial assets with a view profiting from their total return in the form of capital growth and income and in accordance with the Company's risk management and investment policy. In the preparation of the valuation of assets, in accordance with current IPEV guidelines, the Directors are required to make judgements and estimates that are reasonable and incorporate their knowledge of the performance of the investee companies.

· For investments actively traded on organised financial markets, fair value is generally determined by reference to Stock Exchange market quoted bid prices at the close of business on the balance sheet date. Purchases and sales of quoted investments are recognised on the trade date where a contract of sale exists whose terms require delivery within a time frame determined by the relevant market.

· Unquoted investments are reviewed at least quarterly to ensure that the fair values are appropriately stated and are valued in accordance with current IPEV guidelines as updated in December 2018, which relies on subjective estimates. Fair value is established by assessing different methods of valuation, such as price of recent transaction, sales multiples, earnings multiples, discounted cash flows and net assets. Purchases and sales of unlisted investments are recognised when the contract for acquisition or sale becomes unconditional.

· Where a company's underperformance against plan indicates a diminution in the value of the investment, provision against cost is made, as appropriate. Where it is considered the value of an investment has fallen permanently below cost, the loss is treated as a permanent impairment and as a realised loss, even though the investment is still held. The Board assesses the portfolio for such investments and, after agreement with the Investment Manager, will agree the values that represent the extent to which an investment loss has become realised. This is based upon an assessment of objective evidence of that investment's future prospects, to determine whether there is potential for the investment to recover in value.

· Redemption premiums on loan stock investments are recognised at fair value when the Company receives the right to the premium and when considered recoverable.

f) Capital reserves

(i) Realised (included within the Profit and Loss Account reserve)

The following are accounted for in this reserve:

• Gains and losses on realisation of investments;

• Permanent diminution in value of investments; and

• Transaction costs incurred in the acquisition of investments.

(ii) Unrealised capital reserve (Revaluation reserve)

Increases and decreases in the valuation of investments held at the period end are accounted for in this reserve, except to the extent that the diminution is deemed permanent.

In accordance with stating all investments at fair value through profit or loss, all such movements through both unrealised and realised capital reserves are shown within the Income Statement for the period.

(iii) Special reserve

The costs of share buybacks are charged to this reserve. In addition, any realised losses on the sale of investments, and 75% of the management fee expense, and the related tax effect, are transferred from the Profit and Loss Account reserve to this reserve. This reserve can also be used for distributions made by the Company.

2.   Investment Management Fees

Unicorn Asset Management Limited ("UAML") receives an annual management fee, calculated and payable quarterly in arrears, of 2.0% of the net asset value of the Company, excluding the value of the investments in the OEIC which is also managed by UAML, up to net assets of £200 million, 1.5% of net assets in excess of £200 million and 1.0% of net assets in excess of £450 million. If the Company raises further funds during a quarter the net asset value for that quarter shall be reduced by an amount equal to the amount raised, net of costs, multiplied by the percentage of days in that quarter prior to the funds being raised.

The Directors have charged £1,567,000, being 75% of the investment management fees to the capital reserve and the balance of 25% being £523,000 to revenue.

At 31 March 2023, £1,024,000 payable to the Investment Manager is included in creditors due within one year.

3. Taxation

The total allowable expenses exceed income hence there is no tax charge for the period.

4. Income

 5. Basic and diluted earnings and return per share

There are no instruments in place that may increase the number of shares in issue in the future. Accordingly, the above figures represent both basic and diluted earnings per share.

6. Dividends

* The difference between total dividends paid and that shown in the Condensed Cash Flow Statement is £727,000, which is the amount of dividends reinvested under the Dividend Reinvestment Scheme ("DRIS").

7.  Investments at fair value

\* Transaction costs on the purchase and disposal of investments of £nil were incurred in the period.

** Other funds include the Unicorn Ethical Fund and the Royal London Short Term Money Market Fund which are both OEICs and the BlackRock Cash Fund which is a Unit Trust.

Reconciliation of cash movements in investment transactions

The difference between the purchases in Note 7 above and that shown in the Condensed Cash Flow Statement. is £2,000 which is the reinvested dividends in the Royal London Short Term Money Market Fund Y.

Fair value hierarchy

The table below sets out fair value measurements using FRS 102 s11.27 fair value hierarchy. The Company has one class of assets, being at fair value through profit or loss.

* Other funds include the Unicorn Ethical Fund and the Royal London Short Term Money Market Fund which are both OEICs and the BlackRock Cash Fund which is a Unit Trust.

There are currently no financial liabilities at fair value through profit or loss.

Categorisation within the hierarchy has been determined on the lowest level input that is significant to the fair value measurement of the relevant asset as follows:

Level 1 - valued using quoted prices in active markets for identical assets.

Level 2 - valuation by reference to valuation techniques using directly observable inputs other than quoted prices included within Level 1.

Level 3 - valued by reference to valuation techniques using inputs that are not based on observable market data.

The valuation techniques used by the Company are explained in the accounting policies in Note 1.

The fair value of unquoted investments, categorised as Level 3, is established by assessing different methods of valuation, such as price of recent transaction, sales multiples, earnings multiples, discounted cash flows and net assets, therefore no assumptions are disclosed, or sensitivity analysis provided.

A reconciliation of fair value measurements in Level 3 is set out below:

8. Net asset values

9.  Post Balance Sheet Events

There are no post balance sheet events to report.

10.  Related party transactions

During the first six months of the financial year, no transactions with related parties have taken place which have materially affected the financial position or the performance of the Company.

11.  Copies of the Half Yearly Report

Copies of the Half Yearly Report will be available for download on the Company's website: www.unicornaimvct.co.uk.

Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on this announcement (or any other website) is incorporated into, or forms part of this announcement.

A copy of the 2023 Half Yearly Report will be submitted shortly to the National Storage Mechanism ("NSM") and will be available for inspection at the NSM, which is situated at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism